Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer

Journal of Urology

Volumn 181, Issue 4, 2009, Pages 1571-1580

  Bisiaux, Aurélie ^a,b   Thiounn, Nicolas ^c   Timsit, Marc Olivier ^c   Eladaoui, Ahmed ^d   Chang, Huey Hsuan ^a,b   Mapes, James ^e   Mogenet, Agnès ^d   Bresson, Jean Louis ^d   Prié, Dominique ^b   Béchet, Stéphane ^a   Baron, Camille ^a   Sadorge, Christine ^a   Thomas, Stéphanie ^a,b   Albert, Elaine B ^f   Albert, Peter S ^f   Albert, Matthew L ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Rules Based Medicine   (United States)

^f Staten Island University   (United States)

Author keywords

active; immunity; immunotherapy; innate; urinary bladder neoplasms

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA INTERFERON; APOLIPOPROTEIN A1; BCG VACCINE; CD16 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; COMPLEMENT COMPONENT C3; CREATININE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBRINOGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMU-CYST; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLASMA PROTEIN; RANTES; SEX HORMONE BINDING GLOBULIN; STROMELYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLADDER CANCER; BLOOD ANALYSIS; CANCER IMMUNIZATION; CELL COUNT; CELL INFILTRATION; CLINICAL ARTICLE; CREATININE URINE LEVEL; CYTOKINE PRODUCTION; CYTOMETRY; DOSE RESPONSE; FEMALE; GRANULOCYTE; HUMAN; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MALE; MICROENVIRONMENT; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; URINALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; BCG VACCINE; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 62049083648     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.11.124     Document Type: Article

References (19)

1. Patton S.E., Hall M.C., and Ozen H. Bladder cancer. Curr Opin Oncol 14 (2002) 265
2. Alexandroff A.B., Jackson A.M., O'Donnell M.A., and James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353 (1999) 1689
3. Brandau S., and Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61 (2007) 299
4. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180
5. De Boer E.C., De Jong W.H., Steerenberg P.A., Arden L.A., Tetteroo E., De Groot E.R., et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 34 (1992) 306
6. Suttmann H., Riemensberger J., Bentien G., Schmaltz D., Stöckle M., Jocham D., et al. Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66 (2006) 8250
7. Taniguchi K., Koga S., Nishikido M., Yamashita S., Sakuragi T., Kanetake H., et al. Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer. Clin Exp Immunol 115 (1999) 131
8. Jackson A.M., Alexandroff A.B., Kelly R.W., Skibinska A., Esuvaranathan K., Chisholm G.D., et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99 (1995) 369
9. Siracusano S., Vita F., Abbate R., Ciciliato S., Borelli V., Bernabei M., et al. The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 51 (2007) 1589
10. Nor J.E., Christensen J., Mooney D.J., and Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154 (1999) 375
11. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258 (1992) 1798
12. Koch A.E., Kunkel S.L., Harlow L.A., Mazarakis D.D., Haines G.K., Burdick M.D., et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 94 (1994) 1012
13. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436
14. Roy R., Zhang B., and Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 312 (2006) 608
15. Foster S.L., Hargreaves D.C., and Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447 (2007) 972
16. Cavaillon J.M., Adrie C., Fitting C., and Adib-Conquy M. Endotoxin tolerance: is there a clinical relevance?. J Endotoxin Res 9 (2003) 101
17. Thalmann G.N., Sermier A., Rentsch C., Möhrle K., Cecchini M.G., Studer U.E., et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164 (2000) 2129
18. Haaff E.O., Catalona W.J., and Ratliff T.L. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136 (1986) 970
19. Poppas D.P., Pavlovich C.P., Folkman J., Voest E.E., Chen X., Luster A.D., et al. Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52 (1998) 268